Convalescent Plasma for COVID-19 Research (CONCOR-Donor) study, is a national, naturalhistory study of plasma donors recovered from COVID-19. CONCOR-Donor study will addressimmune response, duration of protective immunity, and clinical factors and host geneticscontributing to the variability of immune response. We will also study long-term outcomesfrom COVID-19 infection. Results from the study will help define therapeutic strategiesfor COVID-19.
The outbreak caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) led
to the global pandemic. There are currently no proven treatments for coronavirus disease
(COVID-19), however, convalescent plasma has emerged as a potential therapeutic to
prevent clinical deterioration. Convalescent plasma was successfully used for other
infections, in small numbers, but there is limited evidence for the efficacy of
administering specific, neutralizing antibodies by transfusion of convalescent plasma.
The unknown role for convalescent plasma in treating COVID-19 necessitates further study.
As trials are underway to determine efficacy of using convalescent plasma, we will use
this unique opportunity to conduct a national longitudinal cohort study of 1000 persons
recovered from COVID-19 and volunteer to donate convalescent plasma. Our aims are to:1)
determine if the variability of titers of viral neutralizing antibody and ELISA antibody
are associated with clinical and demographic factors; 2) determine duration of protective
immunity in recovered persons over 1 year and if modified by clinical and demographic
factors; 3) determine genetic risk predictors of the antibody response, and 4) create a
biorepository available to researchers from across Canada. Based on the World Health
Organization (WHO) Coordinated Global Research Map, this project addresses the priority
of the natural history of COVID-19 and clinical characterization of antibody response in
the convalescent phase and beyond.
Inclusion Criteria:
- Recovered from COVID-19 infection
- Have a positive PCR or serology or a positive household contact
- Signed informed consent form
- Provide blood sample
- Ability to complete a questionnaire
Exclusion Criteria:
- None
The Hospital for Sick Children
Toronto, Ontario, Canada
Rulan Parekh, MD, Principal Investigator
The Hospital for Sick Children